These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 11220786)
1. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease. Baslow MH J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786 [TBL] [Abstract][Full Text] [Related]
2. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356 [TBL] [Abstract][Full Text] [Related]
3. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Baslow MH; Guilfoyle DN Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678 [TBL] [Abstract][Full Text] [Related]
4. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
5. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy. Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719 [TBL] [Abstract][Full Text] [Related]
6. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
7. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. Baslow MH; Guilfoyle DN Biochimie; 2013 Apr; 95(4):946-56. PubMed ID: 23151389 [TBL] [Abstract][Full Text] [Related]
8. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740 [TBL] [Abstract][Full Text] [Related]
9. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. Baslow MH; Resnik TR J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392 [TBL] [Abstract][Full Text] [Related]
10. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
11. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model. Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859 [TBL] [Abstract][Full Text] [Related]
12. [Magnetic resonance tomography and localized proton spectroscopy in 2 siblings with Canavan's disease]. Engelbrecht V; Rassek M; Gärtner J; Kahn T; Mödder U Rofo; 1995 Sep; 163(3):238-44. PubMed ID: 7548871 [TBL] [Abstract][Full Text] [Related]
13. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model. Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021 [TBL] [Abstract][Full Text] [Related]
14. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related]
15. Molecular basis of Canavan's disease: from human to mouse. Surendran S; Matalon KM; Tyring SK; Matalon R J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138 [TBL] [Abstract][Full Text] [Related]
16. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. Wittsack HJ; Kugel H; Roth B; Heindel W J Magn Reson Imaging; 1996; 6(6):889-93. PubMed ID: 8956134 [TBL] [Abstract][Full Text] [Related]
17. Atypical MRI findings in Canavan disease: a patient with a mild course. Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711 [TBL] [Abstract][Full Text] [Related]
18. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190 [TBL] [Abstract][Full Text] [Related]
19. Use of localized proton nuclear magnetic resonance spectroscopy in Canavan's disease. Aydinli N; Calişkan M; Calay M; Ozmen M Turk J Pediatr; 1998; 40(4):549-57. PubMed ID: 10028864 [TBL] [Abstract][Full Text] [Related]
20. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice. Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]